vitamin D and calcium Supplementation reduces the complication of letrozole in breast cancer patients
Not Applicable
- Conditions
- Health Condition 1: null- Postmenopausal breast cancer patients
- Registration Number
- CTRI/2012/07/002792
- Lead Sponsor
- Instititional fundJawaharlal Institute Of Post Graduate Medical Education And Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
Postmenopausal Estrogen receptor positive
breast cancer patients receiving Letrozole for
more than 2 months
Exclusion Criteria
Patients with bone metastasis,
History of renal stones,
Serum calcium greater than 11mg/dl,
Patients with renal failure,
Patients taking steroid hormone replacement.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease of Letrozole side effects & improvement in the musculoskeletal symptoms.Timepoint: within 3 months
- Secondary Outcome Measures
Name Time Method improvement in the musculoskeletal symptomsTimepoint: within 3 months